David Barbie
Overview
Explore the profile of David Barbie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marks J, Ahn J, Reuss J, Barbie D, Altan M, Gutierrez M, et al.
Clin Lung Cancer
. 2025 Jan;
PMID: 39753485
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment....
2.
Alsaed B, Lin L, Son J, Li J, Smolander J, Lopez T, et al.
Nat Commun
. 2025 Jan;
16(1):28.
PMID: 39747003
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. Intratumor heterogeneity is a known...
3.
Yang S, Sheffer M, Kaplan I, Wang Z, Tarannum M, Dinh K, et al.
Nat Biotechnol
. 2024 Oct;
PMID: 39367093
The tumor microenvironment can inhibit the efficacy of cancer therapies through mechanisms such as poor trafficking and exhaustion of immune cells. Here, to address this challenge, we exploited the safety,...
4.
Nguyen H, Kan E, Humayun M, Gurvich N, Offeddu G, Wan Z, et al.
Biomaterials
. 2024 Aug;
312:122731.
PMID: 39153324
Tumor-associated inflammation drives cancer progression and therapy resistance, often linked to the infiltration of monocyte-derived tumor-associated macrophages (TAMs), which are associated with poor prognosis in various cancers. To advance immunotherapies,...
5.
Yang S, Sheffer M, Kaplan I, Wang Z, Tarannum M, Dinh K, et al.
Res Sq
. 2024 Apr;
PMID: 38562821
Given the safety, tumor tropism, and ease of genetic manipulation in non-pathogenic (), we designed a novel approach to deliver biologics to overcome poor trafficking and exhaustion of immune cells...
6.
Nguyen H, Gurvich N, Gillrie M, Offeddu G, Humayun M, Kan E, et al.
bioRxiv
. 2023 Dec;
PMID: 38076998
Tumor-associated inflammation drives cancer progression and therapy resistance, with the infiltration of monocyte-derived tumor-associated macrophages (TAMs) associated with poor prognosis in diverse cancers. Targeting TAMs holds potential against solid tumors,...
7.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, et al.
Cancer Res
. 2023 Jul;
83(19):3284-3304.
PMID: 37450351
Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR+...
8.
Ricciuti B, Arbour K, Lin J, Vajdi A, Vokes N, Hong L, et al.
J Thorac Oncol
. 2021 Nov;
17(3):399-410.
PMID: 34740862
Introduction: STK11 and KEAP1 mutations (STK11 mutant [STK11] and KEAP1) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been associated with resistance to programmed...
9.
Sun R, Xu M, Li X, Gaynor S, Zhou H, Li Z, et al.
Genet Epidemiol
. 2020 Sep;
45(1):99-114.
PMID: 32924180
Clinical trial results have recently demonstrated that inhibiting inflammation by targeting the interleukin-1β pathway can offer a significant reduction in lung cancer incidence and mortality, highlighting a pressing and unmet...
10.
Liu S, Marneth A, Alexe G, Walker S, Gandler H, Ye D, et al.
Blood Adv
. 2018 Dec;
2(23):3428-3442.
PMID: 30504235
To identify novel therapeutic targets in acute myeloid leukemia (AML), we examined kinase expression patterns in primary AML samples. We found that the serine/threonine kinase IKBKE, a noncanonical IkB kinase,...